References
- Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354:93–99.
- Janus N, Thariat J, Boulanger H, et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010;21:1395–1403.
- Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296:2823–2831.
- Janus N, Launay-Vacher V. Anticancer drugs in end-stage kidney disease patients. Semin Dialysis. 2015;28:413–416.
- Haubitz M, Bohnenstengel F, Brunkhorst R, et al. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int. 2002;61:1495–1501.
- de Barros Pontes L, Todaro J, Karnakis T, et al. Treatment of a frail older patient with diffuse large B-cell lymphoma on maintenance dialysis: attenuated immunochemotherapy and adapted care plan. Case Rep Oncol. 2013;6:197–203.
- Feldmann G, Nattermann J, Gerhardt T, et al. Partial remission of a newly diagnosed diffuse large B-cell Non-Hodgkin’s lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP. Int J Lab Hematol. 2007;29:469–473.
- Kawano N, Yokota-Ikeda N, Kawano S, et al. Successful treatment of non-Hodgkin’s lymphoma with rituximab and dose-adjusted CHOP therapy in a patient with concomitant end-stage renal disease requiring haemodialysis. NDT Plus. 2011;4:186–189.
- Institute NC. 1/14/2016. Common Terminology Criteria for Adverse Events v4.0; 2009 [cited 2016 Jan 14]. Available from: <http://evs.nci.nih.gov/ftp1/CTCAE/About.html>.
- Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
- de Jonge ME, Huitema AD, Rodenhuis S, et al. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44:1135–1164.